[Form 4] CRISPR Therapeutics AG Insider Trading Activity

Q: What did CRISPR Therapeutics (CRSP) disclose in this Form 4?

A stock option grant to the Chief Medical Officer for 16,500 common shares at an exercise price of $67.74 .

Q: What is the vesting schedule for the CRSP option grant?

The option vests in 48 equal monthly installments , starting on November 3, 2025 .

Q: When does the reported CRSP stock option expire?

The option expires on October 3, 2035 .

Q: How many derivative securities were beneficially owned after the transaction?

16,500 derivative securities were beneficially owned following the reported transaction.

Q: What is the ownership form for the reported CRSP securities?

The ownership is reported as Direct (D) .

Q: What role does the reporting person hold at CRISPR Therapeutics (CRSP)?

The reporting person is the company’s Chief Medical Officer .

Filing Impact

(Low)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

CRISPR Therapeutics AG (CRSP)16,500 common shares with an exercise price of $67.74 on October 3, 2025. The option expires on October 3, 2035.

The award vests in 48 equal monthly installments, beginning November 3, 2025. Following the grant, 16,500 derivative securities were beneficially owned, shown as Direct (D) ownership.

CRISPR Therapeutics AG (CRSP) ha riferito di un award azionario interno. Il Chief Medical Officer dell'azienda ha ricevuto una stock option che copre 16.500 azioni ordinarie con un prezzo di esercizio di $67,74 in data 3 ottobre 2025. L'opzione scade il 3 ottobre 2035.
L'assegnazione matura in 48 rate mensili uguali, a partire dal 3 novembre 2025. Dopo la concessione, 16.500 strumenti derivati erano di proprietà beneficiaria, indicate come proprietà Diretta (D).

CRISPR Therapeutics AG (CRSP) informó sobre una asignación de acciones para insiders. El Director Médico de la empresa recibió una opción de compra que cubre 16.500 acciones comunes con un precio de ejercicio de $67,74 el 3 de octubre de 2025. La opción vence el 3 de octubre de 2035.
La adjudicación se consolida en 48 cuotas mensuales iguales, a partir del 3 de noviembre de 2025. Tras la concesión, 16.500 valores derivados eran de propiedad beneficiaria, mostrados como propiedad Directa (D).

CRISPR Therapeutics AG (CRSP) 이내 인사 보상에 대한 내부자 주식 보상이 보고되었다. 회사의 최고의료책임자(CMO)가 16,500주 보통주를 커버하는 주식매수선택권을 67.74달러의 실행가격으로 2025년 10월 3일에 받았다. 이 옵션은 2035년 10월 3일에 만료된다.
보상은 매달 동일한 48회 분할로 베수되며, 시작은 2025년 11월 3일부터다. 부여 후, 16,500 파생증권이 혜택 소유로 나타나며, Direct (D) 소유로 표시된다.

CRISPR Therapeutics AG (CRSP) a annoncé une attribution d'options pour initiés. Le directeur médical de l'entreprise a reçu une option d'achat couvrant 16 500 actions ordinaires avec un prix d'exercice de 67,74 $ au 3 octobre 2025. L'option expire le 3 octobre 2035.
L'attribution est acquise par 48 versements mensuels égaux, à compter du 3 novembre 2025. Après la concession, 16 500 valeurs dérivées étaient détenues de manière bénéficiaire, affichées comme propriété Directe (D).

CRISPR Therapeutics AG (CRSP) meldete eine Insider-Eigenkapitalzuteilung. Der Chief Medical Officer des Unternehmens erhielt eine Aktienoption über 16.500 Stammaktien mit einem Ausübungspreis von 67,74 $ am 3. Oktober 2025. Die Option läuft am 3. Oktober 2035 ab.
Die Zuwendung vestet in 48 gleichen monatlichen Raten, beginnend am 3. November 2025. Nach der Gewährung waren 16.500 Derivate-Wertpapiere vorteilhaft Eigentum, angezeigt als Direct (D) Eigentum.

CRISPR Therapeutics AG (CRSP) تم الإبلاغ عن منح أسهم للمطلعين. تلقى المدير الطبي بالشركة خيار أسهم يغطي 16,500 سهم عادي بسعر ممارسة 67.74 دولارًا في 3 أكتوبر 2025. ينتهي الخيار في 3 أكتوبر 2035.
تتحقق المنحة في 48 دفعة شهرية متساوية، بدءاً من 3 نوفمبر 2025. بعد المنحة، كانت 16,500 أدوات مشتقة مملوكة لصالح المستفيد، معروضة كملكية مباشرة (D).

CRISPR Therapeutics AG (CRSP) 报告了一项内部人股权奖励。公司的首席医疗官获得了一份覆盖 16,500 股普通股 的期权，执行价格为 $67.74，日期为 2025年10月3日。该期权于 2035年10月3日 到期。
该授予分期在 48 个月等额分期，自 2025年11月3日 起开始。授予后，16,500 递延证券 实际上由受益所有，被列示为 直接（D） 所有权。

Positive

None.

Negative

None.

10/03/2025 - 05:37 PM

SEC Form 4

FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number: 3235-0287

Estimated average burden

hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*
Patel Naimish

(Last) (First) (Middle)

C/O CRISPR THERAPEUTICS

105 WEST FIRST STREET

(Street)
BOSTON MA 02127

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
CRISPR Therapeutics AG [ CRSP ] 5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

Director 10% Owner

X Officer (give title below) Other (specify below)

Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
10/03/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)

X Form filed by One Reporting Person

Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)

Code V Amount (A) or (D) Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)

Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares

Stock Option (Right to Buy) $67.74 10/03/2025 A 16,500 ⁽¹⁾ 10/03/2035 Common Shares 16,500 $0.00 16,500 D

Explanation of Responses:

1. This option was granted on October 3, 2025 with respect to 16,500 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of November 3, 2025.

/s/ Elizabeth Ryland Waldinger, attorney-in-fact 10/03/2025

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What did CRISPR Therapeutics (CRSP) disclose in this Form 4?

A stock option grant to the Chief Medical Officer for 16,500 common shares at an exercise price of $67.74.

What is the vesting schedule for the CRSP option grant?

The option vests in 48 equal monthly installments, starting on November 3, 2025.

When does the reported CRSP stock option expire?

The option expires on October 3, 2035.

How many derivative securities were beneficially owned after the transaction?

16,500 derivative securities were beneficially owned following the reported transaction.

What is the ownership form for the reported CRSP securities?

The ownership is reported as Direct (D).

What role does the reporting person hold at CRISPR Therapeutics (CRSP)?

The reporting person is the company’s Chief Medical Officer.

[Form 4] CRISPR Therapeutics AG Insider Trading Activity

FAQ

What did CRISPR Therapeutics (CRSP) disclose in this Form 4?

What is the vesting schedule for the CRSP option grant?

When does the reported CRSP stock option expire?

How many derivative securities were beneficially owned after the transaction?

What is the ownership form for the reported CRSP securities?

What role does the reporting person hold at CRISPR Therapeutics (CRSP)?

NASDAQ:CRSP

CRSP Rankings

CRSP Latest News

CRSP Latest SEC Filings

CRSP Stock Data

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$67.74	10/03/2025		A		16,500		⁽¹⁾	10/03/2035	Common Shares	16,500	$0.00	16,500	D

	/s/ Elizabeth Ryland Waldinger, attorney-in-fact	10/03/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Trending News

[Form 4] CRISPR Therapeutics AG Insider Trading Activity

FAQ

What did CRISPR Therapeutics (CRSP) disclose in this Form 4?

What is the vesting schedule for the CRSP option grant?

When does the reported CRSP stock option expire?

How many derivative securities were beneficially owned after the transaction?

What is the ownership form for the reported CRSP securities?

What role does the reporting person hold at CRISPR Therapeutics (CRSP)?

NASDAQ:CRSP

CRSP Rankings

CRSP Latest News

CRSP Latest SEC Filings

CRSP Stock Data